PL3971212T3 - Białka wiążące antygen receptora onkostatyny m - Google Patents

Białka wiążące antygen receptora onkostatyny m

Info

Publication number: PL3971212T3
Authority: PL; Poland
Prior art keywords: oncostatin; antigen binding; binding proteins; receptor antigen; receptor
Prior art date: 2013-05-30

Application number

PL21190497.4T

Other languages

English (en)

Inventor

Heather A. Arnett

Sabine S. Escobar

Chadwick T. King

Ai Ching Lim

Saravanakumar NARAYANAN

Paul H. Weinreb

Nels E. Pederson

Original Assignee

Kiniksa Pharmaceuticals, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-30

Filing date

2014-05-30

Publication date

2024-05-27

2014-05-30 Application filed by Kiniksa Pharmaceuticals, Ltd. filed Critical Kiniksa Pharmaceuticals, Ltd.

2024-05-27 Publication of PL3971212T3 publication Critical patent/PL3971212T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL21190497.4T 2013-05-30 2014-05-30 Białka wiążące antygen receptora onkostatyny m PL3971212T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361829082P	2013-05-30	2013-05-30

Publications (1)

Publication Number	Publication Date
PL3971212T3 true PL3971212T3 (pl)	2024-05-27

Family

ID=51059621

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18185359T PL3456743T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m
PL21190497.4T PL3971212T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m
PL14734671T PL3004167T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL18185359T PL3456743T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL14734671T PL3004167T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m

Country Status (23)

Country	Link
US (6)	US9663571B2 (pl)
EP (4)	EP3456743B1 (pl)
JP (5)	JP6243521B2 (pl)
KR (3)	KR102258460B1 (pl)
CN (4)	CN118271441A (pl)
AU (4)	AU2014273966B2 (pl)
BR (1)	BR112015029643B1 (pl)
CA (1)	CA2910732A1 (pl)
DK (2)	DK3004167T3 (pl)
EA (1)	EA201592285A1 (pl)
ES (3)	ES2973474T3 (pl)
HK (3)	HK1221961A1 (pl)
HU (2)	HUE040548T2 (pl)
IL (2)	IL267382B (pl)
MX (2)	MX351127B (pl)
NZ (2)	NZ753995A (pl)
PL (3)	PL3456743T3 (pl)
PT (2)	PT3456743T (pl)
SG (1)	SG11201508829QA (pl)
SI (2)	SI3456743T1 (pl)
TR (1)	TR201815608T4 (pl)
WO (1)	WO2014194274A2 (pl)
ZA (1)	ZA201508064B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ753995A (en)	2013-05-30	2022-07-01	Kiniksa Pharmaceuticals Ltd	Oncostatin m receptor antigen binding proteins
EP3974450A3 (en)	2015-01-29	2022-06-22	Oxford University Innovation Limited	Biomarker
AU2017290389B2 (en)	2016-07-01	2024-09-26	Resolve Therapeutics, Llc	Optimized binuclease fusions and methods
US10093731B2 (en)	2017-02-24	2018-10-09	Kindred Biosciences, Inc.	Anti-IL31 antibodies for veterinary use
US10493149B2 (en) *	2017-04-11	2019-12-03	Kiniksa Pharmaceuticals, Ltd.	Stable anti-OSMR antibody formulation
WO2019040674A1 (en)	2017-08-22	2019-02-28	Sanabio, Llc	SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
KR20210018808A (ko) *	2018-04-25	2021-02-18	키닉사 파마슈티컬스, 리미티드	항-OSMRß 항체 전달에 의한 피부 질환 또는 장애 치료
WO2020036833A1 (en) *	2018-08-13	2020-02-20	Kiniksa Pharmaceuticals, Ltd.	Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
US20220002387A1 (en) *	2018-11-06	2022-01-06	University Of Miami	Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
CN110563844A (zh) *	2019-09-04	2019-12-13	华中农业大学	一种抗犬白介素31受体的多克隆抗体及其应用
TW202221039A (zh) *	2020-10-19	2022-06-01	美商碩騰服務公司	犬及貓抑瘤素Ｍ受體β之抗體及其用途
CA3227171A1 (en) *	2021-07-30	2023-02-02	Zhiqiang KU	Osmr-specific monoclonal antibodies and methods of their use
WO2024002259A1 (zh) *	2022-06-29	2024-01-04	百奥赛图(北京)医药科技股份有限公司	一种osm、osmr、il31ra和/或il31基因修饰的非人动物
WO2024186963A1 (en)	2023-03-07	2024-09-12	Genentech, Inc.	Methods for treating pulmonary fibrotic diseases or disorders with an anti oncostatin m receptor beta antibody

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US233A (en)		1837-06-14		Improvement in plows
US4447A (en)		1846-04-04		Car- wheel
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
EP0028683A1 (en)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotic C-15003 PHO and production thereof
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
WO1982001188A1 (en)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US5681930A (en)	1985-12-20	1997-10-28	Bristol-Myers Squibb Company	Anti-oncostatin M monoclonal antibodies
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
ZA912136B (en) *	1990-03-29	1992-11-25	Bristol Myers Squibb Co	Anti-oncostatin m monoclonal antibodies
WO1991018982A1 (en)	1990-06-05	1991-12-12	Immunex Corporation	Type ii interleukin-1 receptors
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
WO1992015673A1 (en)	1991-03-11	1992-09-17	The University Of Georgia Research Foundation, Inc.	Cloning and expression of renilla luciferase
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
ATE463573T1 (de)	1991-12-02	2010-04-15	Medimmune Ltd	Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563475B1 (en)	1992-03-25	2000-05-31	Immunogen Inc	Cell binding agent conjugates of derivatives of CC-1065
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US6239328B1 (en)	1992-10-05	2001-05-29	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
NZ257942A (en)	1992-10-23	1996-04-26	Immunex Corp	Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5837242A (en)	1992-12-04	1998-11-17	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
CA2169298A1 (en)	1993-09-10	1995-03-16	Martin Chalfie	Uses of green fluorescent protein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5783672A (en)	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
US6037525A (en)	1996-08-01	2000-03-14	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
WO1998024893A2 (en)	1996-12-03	1998-06-11	Abgenix, Inc.	TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
NZ335453A (en)	1996-12-12	2001-07-27	Prolume Ltd	Microelectronic device with microlocations including photodetector for detecting bioluminescence
US6245974B1 (en)	1997-08-06	2001-06-12	North Carolina State University	Matrix attachment regions
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
GB9806530D0 (en)	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
WO1999049019A2 (en)	1998-03-27	1999-09-30	Prolume, Ltd.	Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
US6177612B1 (en)	1998-07-31	2001-01-23	Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada	Matrix attachment regions
WO2000018938A1 (en)	1998-09-29	2000-04-06	Pioneer Hi-Bred International, Inc.	Mar/sar elements flanking rsyn7-driven construct
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2388063C (en)	1999-11-24	2010-06-08	Immunogen, Inc.	Cytotoxic agents comprising taxanes and their therapeutic use
US20030096339A1 (en)	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
KR100408844B1 (ko)	2000-07-29	2003-12-06	한국산업기술평가원	동물세포 발현벡터
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
WO2002048379A1 (en)	2000-12-15	2002-06-20	Pangen Biotech Inc.	Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
WO2002074969A2 (en)	2001-01-26	2002-09-26	University Of Lausanne	Matrix attachment regions and methods for use thereof
ATE477280T1 (de)	2001-06-28	2010-08-15	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
US7230167B2 (en)	2001-08-31	2007-06-12	Syngenta Participations Ag	Modified Cry3A toxins and nucleic acid sequences coding therefor
JP4511349B2 (ja)	2002-01-18	2010-07-28	ザイモジェネティクス，インコーポレイティド	サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー
PT2230299E (pt)	2002-01-18	2012-03-02	Zymogenetics Inc	Novo ligando de citocina zcytor17
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP2135879A3 (en)	2002-06-28	2010-06-23	Domantis Limited	Ligand
ATE499116T1 (de)	2002-08-16	2011-03-15	Immunogen Inc	Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1578801A2 (en)	2002-12-27	2005-09-28	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7755007B2 (en)	2003-04-17	2010-07-13	K&H Manufacturing, Inc	Heated pet mat
EP1694850B1 (en)	2003-11-12	2011-06-29	Schering Corporation	Plasmid system for multigene expression
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
JP4803789B2 (ja) *	2004-02-03	2011-10-26	独立行政法人科学技術振興機構	疼痛を処置するための薬学的組成物
CA2558399C (en)	2004-03-02	2015-05-19	Seattle Genetics, Inc.	Partially loaded antibodies and methods of their conjugation
ATE515515T1 (de)	2004-03-30	2011-07-15	Glaxo Group Ltd	Immunglobuline gegen menschlisches osm
KR20120064120A (ko)	2004-06-01	2012-06-18	제넨테크, 인크.	항체 약물 접합체 및 방법
US20080305044A1 (en)	2004-11-29	2008-12-11	Seattle Genetics, Inc.	Engineered Antibodies and Immunoconjugates
US7301019B2 (en)	2005-01-21	2007-11-27	Immunogen, Inc.	Method for the preparation of maytansinoid esters
AU2006210606B2 (en) *	2005-02-03	2012-03-22	Macrogenics West, Inc.	Antibodies to Oncostatin M receptor
US20060182743A1 (en)	2005-02-14	2006-08-17	Janine Bilsborough	Methods of treating skin disorders using an IL-31RA antagonist
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
ES2561628T3 (es)	2005-05-06	2016-02-29	Zymogenetics, Inc.	Anticuerpos monoclonales IL-31 y métodos de uso
JP5053264B2 (ja)	2005-05-19	2012-10-17	アムジェンインコーポレイテッド	抗体の安定性を増加させるための組成物および方法
MX2007015476A (es)	2005-06-14	2008-02-25	Amgen Inc	Formulaciones de proteina autoamortiguadoras.
NZ599176A (en)	2005-08-03	2014-04-30	Immunogen Inc	Immunoconjugate formulations
CA2617953C (en)	2005-08-09	2013-12-17	Millennium Pharmaceuticals, Inc.	Method of acylating maytansinol with chiral amino acids
EP2001906A2 (en) *	2006-01-10	2008-12-17	Zymogenetics, Inc.	Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
CN101395920A (zh)	2006-03-01	2009-03-25	汤姆森特许公司	生成媒体包的设备与方法
GEP20125628B (en)	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
US9028821B2 (en) *	2006-06-08	2015-05-12	Chugai Seiyaku Kabushiki Kaisha	Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
KR101501660B1 (ko)	2006-09-01	2015-03-11	지모제넥틱스, 인코포레이티드	Ｉｌ―31 단클론 항체의 가변 영역 서열 및 사용 방법
US8247537B2 (en) *	2006-11-15	2012-08-21	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
CL2008002085A1 (es)	2007-07-16	2008-11-21	Genentech Inc	Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
US7695963B2 (en)	2007-09-24	2010-04-13	Cythera, Inc.	Methods for increasing definitive endoderm production
CN101970488B (zh)	2007-12-07	2014-06-18	津莫吉尼蒂克斯公司	对il-31特异的人源化抗体分子
PL2235064T3 (pl)	2008-01-07	2016-06-30	Amgen Inc	Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
AU2009210636B2 (en)	2008-01-31	2014-08-28	Genentech, Inc.	Anti-CD79b antibodies and immunoconjugates and methods of use
KR20220035504A (ko)	2008-04-30	2022-03-22	이뮤노젠 아이엔씨	가교제 및 그 용도
WO2010085682A2 (en)	2009-01-23	2010-07-29	Biogen Idec Ma Inc.	Stabilized fc polypeptides with reduced effector function and methods of use
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
RU2012139181A (ru)	2010-02-26	2014-04-10	Ново Нордиск А/С	Стабильная композиция, содержащая антитело
WO2013168829A1 (en) *	2012-05-11	2013-11-14	Wakayama Medical University	Anti oncostatin m receptor beta antibody
JP5782185B2 (ja)	2012-06-01	2015-09-24	日本電信電話株式会社	パケット転送処理方法およびパケット転送処理装置
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
NZ753995A (en)	2013-05-30	2022-07-01	Kiniksa Pharmaceuticals Ltd	Oncostatin m receptor antigen binding proteins
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US9209965B2 (en)	2014-01-14	2015-12-08	Microsemi Semiconductor Ulc	Network interface with clock recovery module on line card
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof
EP3797792A1 (en)	2017-03-01	2021-03-31	MedImmune Limited	Formulations of anti-gm-csfralpha monoclonal antibody
US10493149B2 (en)	2017-04-11	2019-12-03	Kiniksa Pharmaceuticals, Ltd.	Stable anti-OSMR antibody formulation

2014
- 2014-05-30 NZ NZ753995A patent/NZ753995A/en active IP Right Revival
- 2014-05-30 EP EP18185359.9A patent/EP3456743B1/en active Active
- 2014-05-30 EP EP14734671.2A patent/EP3004167B1/en active Active
- 2014-05-30 DK DK14734671.2T patent/DK3004167T3/en active
- 2014-05-30 HU HUE14734671A patent/HUE040548T2/hu unknown
- 2014-05-30 EP EP23210981.9A patent/EP4349864A3/en active Pending
- 2014-05-30 PT PT18185359T patent/PT3456743T/pt unknown
- 2014-05-30 PL PL18185359T patent/PL3456743T3/pl unknown
- 2014-05-30 MX MX2015016304A patent/MX351127B/es active IP Right Grant
- 2014-05-30 JP JP2016517062A patent/JP6243521B2/ja active Active
- 2014-05-30 KR KR1020187021007A patent/KR102258460B1/ko active IP Right Grant
- 2014-05-30 ES ES21190497T patent/ES2973474T3/es active Active
- 2014-05-30 CN CN202410270260.4A patent/CN118271441A/zh active Pending
- 2014-05-30 SG SG11201508829QA patent/SG11201508829QA/en unknown
- 2014-05-30 CA CA2910732A patent/CA2910732A1/en active Pending
- 2014-05-30 ES ES14734671.2T patent/ES2692657T3/es active Active
- 2014-05-30 BR BR112015029643-2A patent/BR112015029643B1/pt active IP Right Grant
- 2014-05-30 EA EA201592285A patent/EA201592285A1/ru unknown
- 2014-05-30 AU AU2014273966A patent/AU2014273966B2/en active Active
- 2014-05-30 SI SI201431906T patent/SI3456743T1/sl unknown
- 2014-05-30 CN CN201910733125.8A patent/CN110511279B/zh active Active
- 2014-05-30 PL PL21190497.4T patent/PL3971212T3/pl unknown
- 2014-05-30 PT PT14734671T patent/PT3004167T/pt unknown
- 2014-05-30 US US14/891,491 patent/US9663571B2/en active Active
- 2014-05-30 NZ NZ713636A patent/NZ713636A/en active IP Right Revival
- 2014-05-30 PL PL14734671T patent/PL3004167T3/pl unknown
- 2014-05-30 EP EP21190497.4A patent/EP3971212B1/en active Active
- 2014-05-30 TR TR2018/15608T patent/TR201815608T4/tr unknown
- 2014-05-30 HU HUE18185359A patent/HUE056580T2/hu unknown
- 2014-05-30 CN CN201710655839.2A patent/CN107513105B/zh active Active
- 2014-05-30 DK DK18185359.9T patent/DK3456743T3/da active
- 2014-05-30 ES ES18185359T patent/ES2895824T3/es active Active
- 2014-05-30 KR KR1020217015688A patent/KR102652165B1/ko active IP Right Grant
- 2014-05-30 SI SI201430916T patent/SI3004167T1/sl unknown
- 2014-05-30 WO PCT/US2014/040360 patent/WO2014194274A2/en active Application Filing
- 2014-05-30 KR KR1020157034312A patent/KR101882366B1/ko active IP Right Grant
- 2014-05-30 CN CN201480031080.5A patent/CN105555803B/zh active Active
2015
- 2015-10-30 ZA ZA2015/08064A patent/ZA201508064B/en unknown
- 2015-11-26 MX MX2020003503A patent/MX2020003503A/es unknown
2016
- 2016-08-24 HK HK16110088.4A patent/HK1221961A1/zh unknown
- 2016-09-28 US US15/279,305 patent/US9593163B2/en active Active
- 2016-11-01 HK HK16112538.6A patent/HK1224310A1/zh unknown
- 2016-11-01 HK HK18107986.1A patent/HK1249522A1/zh unknown
2017
- 2017-04-12 US US15/486,094 patent/US9738721B1/en active Active
- 2017-05-29 JP JP2017105838A patent/JP6606122B2/ja active Active
- 2017-07-11 US US15/646,699 patent/US10421813B2/en active Active
- 2017-09-15 AU AU2017228686A patent/AU2017228686B2/en active Active
2019
- 2019-06-16 IL IL267382A patent/IL267382B/en unknown
- 2019-08-07 US US16/534,900 patent/US20190359724A1/en not_active Abandoned
- 2019-10-17 JP JP2019189968A patent/JP2020022482A/ja active Pending
2020
- 2020-02-11 AU AU2020200980A patent/AU2020200980B2/en active Active
2021
- 2021-09-03 US US17/466,395 patent/US12122837B2/en active Active
- 2021-11-03 IL IL287824A patent/IL287824A/en unknown
2022
- 2022-04-14 AU AU2022202503A patent/AU2022202503A1/en active Pending
- 2022-09-27 JP JP2022153731A patent/JP7474817B2/ja active Active
2024
- 2024-04-15 JP JP2024065396A patent/JP2024095814A/ja active Pending

Also Published As

Publication number	Publication date
TR201815608T4 (tr)	2018-11-21
SI3456743T1 (sl)	2022-01-31
CA2910732A1 (en)	2014-12-04
SG11201508829QA (en)	2015-12-30
HUE040548T2 (hu)	2019-03-28
CN110511279A (zh)	2019-11-29
WO2014194274A2 (en)	2014-12-04
HK1221961A1 (zh)	2017-06-16
IL267382A (en)	2019-08-29
JP6243521B2 (ja)	2017-12-06
ES2895824T3 (es)	2022-02-22
AU2020200980B2 (en)	2022-04-28
AU2017228686A1 (en)	2017-10-05
MX351127B (es)	2017-10-03
JP6606122B2 (ja)	2019-11-13
JP2016520619A (ja)	2016-07-14
US10421813B2 (en)	2019-09-24
EP3971212A1 (en)	2022-03-23
PL3004167T3 (pl)	2019-01-31
CN105555803A (zh)	2016-05-04
KR20160011644A (ko)	2016-02-01
JP2022180573A (ja)	2022-12-06
EP4349864A3 (en)	2024-06-26
ES2692657T3 (es)	2018-12-04
DK3004167T3 (en)	2018-11-12
JP2024095814A (ja)	2024-07-10
PT3456743T (pt)	2021-10-27
US9663571B2 (en)	2017-05-30
EP3004167B1 (en)	2018-07-25
AU2020200980A1 (en)	2020-02-27
CN105555803B (zh)	2019-09-10
US20160137739A1 (en)	2016-05-19
HK1249522A1 (zh)	2018-11-02
AU2014273966A1 (en)	2015-11-12
US20220056144A1 (en)	2022-02-24
HK1224310A1 (zh)	2017-08-18
EP3456743A1 (en)	2019-03-20
BR112015029643B1 (pt)	2023-12-12
EP3456743B1 (en)	2021-08-18
CN107513105B (zh)	2019-08-16
US9738721B1 (en)	2017-08-22
PT3004167T (pt)	2018-11-13
NZ713636A (en)	2022-07-01
JP7474817B2 (ja)	2024-04-25
AU2014273966B2 (en)	2017-08-31
EP3971212C0 (en)	2023-12-27
KR102652165B1 (ko)	2024-03-27
ZA201508064B (en)	2019-07-31
US12122837B2 (en)	2024-10-22
AU2017228686B2 (en)	2019-11-14
KR102258460B1 (ko)	2021-06-02
KR20180086295A (ko)	2018-07-30
IL267382B (en)	2021-12-01
CN110511279B (zh)	2024-03-29
DK3456743T3 (da)	2021-09-27
MX2015016304A (es)	2016-03-21
NZ753995A (en)	2022-07-01
KR101882366B1 (ko)	2018-07-30
HUE056580T2 (hu)	2022-02-28
US20170008958A1 (en)	2017-01-12
EP3971212B1 (en)	2023-12-27
ES2973474T3 (es)	2024-06-20
WO2014194274A3 (en)	2015-03-12
BR112015029643A2 (pt)	2017-09-26
JP2017140056A (ja)	2017-08-17
EP4349864A2 (en)	2024-04-10
CN107513105A (zh)	2017-12-26
US20180002429A1 (en)	2018-01-04
US20190359724A1 (en)	2019-11-28
EP3004167A2 (en)	2016-04-13
CN118271441A (zh)	2024-07-02
SI3004167T1 (sl)	2019-01-31
EA201592285A1 (ru)	2016-05-31
PL3456743T3 (pl)	2022-03-07
KR20210064400A (ko)	2021-06-02
MX2020003503A (es)	2020-07-22
US20170218076A1 (en)	2017-08-03
US9593163B2 (en)	2017-03-14
AU2022202503A1 (en)	2022-05-12
IL287824A (en)	2022-01-01
JP2020022482A (ja)	2020-02-13

Publication	Publication Date	Title
IL287824A (en)	2022-01-01	Oncostatin m receptor antigen-binding proteins
IL282226A (en)	2021-05-31	ST2 antigen-binding proteins
HK1225641A1 (zh)	2017-09-15	Gitr抗原結合蛋白
IL240838A0 (en)	2015-10-29	Anti-3–lag binding proteins
HK1215592A1 (zh)	2016-09-02	蛋白偶聯受體庫